NCT05387083View on ClinicalTrials.gov

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

June 26, 2024

Study Completion Date

June 26, 2024

Conditions
Healthy Volunteer
Interventions
DRUG

Low Dose TP-05

Healthy Volunteers will receive a single low dose of TP-05 on Day 1.

DRUG

High Dose TP-05

Healthy Volunteers will receive a single high dose of TP-05 on Day 1.

DRUG

Placebo Comparator

Healthy Volunteers will receive a single dose of placebo on Day 1.

Trial Locations (1)

02111

Tufts University School of Medicine, Boston

All Listed Sponsors
lead

Tarsus Pharmaceuticals, Inc.

INDUSTRY